Could a cholesterol drug boost chemo in resistant lung cancer?
NCT ID NCT07351565
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is for people with non-small cell lung cancer that has stopped responding to second-line treatment. Researchers will use a lab test on a patient's own tumor cells to pick the best chemotherapy drugs, then add the statin pitavastatin. The goal is to see if this personalized combo can shrink tumors. About 22 adults aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?